Q-omics provides the consensus-scored ZNF436-AS1 profile across patient tissues and cancer cell-line models. ZNF436-AS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF436-AS1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZNF436-AS1 RNA expression shows 19,436 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where ZNF436-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF436-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF436-AS1 survival associations across molecular data types. ZNF436-AS1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF436-AS1 RNA expression–survival associations across cancer types. High ZNF436-AS1 expression shows unfavorable associations in KIRC and LGG, but favorable associations in HNSC, BLCA, PAAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF436-AS1 RNA expression.
This table summarizes ZNF436-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF436-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF436-AS1 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, LIHC, LUSC and LUAD. The KIRC box plot shows higher ZNF436-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.761, t-test p < 0.001).
This table shows molecular features associated with ZNF436-AS1 in patient tissues and cancer cell lines. In patient samples, ZNF436-AS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF436-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS.
